logo
logo
RadNet, Inc.

RadNet, Inc.

NASDAQ•RDNT
CEO: Dr. Howard G. Berger M.D.
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1997-01-03
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
連絡先情報
1510 Cotner Avenue, Los Angeles, CA, 90025, United States
310-478-7808
www.radnet.com
時価総額
$5.38B
PER (TTM)
-408.7
21.2
配当利回り
--
52週高値
$85.84
52週安値
$45.00
52週レンジ
60%
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$522.87M+13.39%
直近4四半期の推移

EPS

$0.07+63.16%
直近4四半期の推移

フリーCF

-$7.62M-146.64%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Growth Total service revenue reached $1.492B USD for nine months, showing 9.9% growth over prior period, driven by acquisitions.
Cash Reserves Increased Cash and equivalents totaled $804.7M USD as of September 30, 2025, up from $740.0M USD at year-end 2024.
Digital Health Segment Growth Digital Health external revenue grew 38.2% to $64.8M USD for nine months, reflecting strong contribution from iCAD integration.
Imaging Center Revenue Up Imaging Center same center revenue increased 9.6% to $490.0M USD for the quarter, driven by procedure mix shift.

リスク要因

Net Loss Deterioration Net loss attributable to common stockholders widened significantly to $(18.1M) USD for nine months versus $(2.6M) USD prior.
Operating Costs Rising Total operating expenses rose 12.7% to $1.370B USD for nine months, pressured by staffing and medical supplies inflation.
Stock Comp Expense Surge Stock-based compensation expense increased 94.2% to $38.1M USD for nine months due to greater shares granted and fair values.
Lease Abandonment Charges Recognized $8.3M USD in lease abandonment charges during nine months, impacting Imaging Center segment profitability.

見通し

Integrating Recent Acquisitions Expect continued net loss in Digital Health near term while integrating iCAD and See-Mode platforms for broader deployment.
Funding Future Growth Existing capital resources expected to sustain operations; fund future acquisitions via cash flow or new debt/equity issuances.
Evaluating New Tax Legislation Evaluating impact of OBBBA tax law changes; adoption expected prospectively for annual reporting starting in fiscal 2025.
Contingent Consideration Assessed Contingent consideration for recent acquisitions assessed quarterly; milestone probabilities remain unchanged as of September 30, 2025.

同業比較

売上高 (TTM)

Oscar Health, Inc.OSCR
$11.70B
+27.5%
Bausch + Lomb CorporationBLCO
$4.98B
+6.2%
Bruker CorporationBRKR
$3.44B
+2.1%

粗利益率 (最新四半期)

Krystal Biotech, Inc.KRYS
94.2%
+2.2pp
iRhythm Technologies, Inc.IRTC
71.1%
+2.3pp
Bausch + Lomb CorporationBLCO
60.2%
-1.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
KRYS$8.02B40.219.4%0.8%
PCVX$7.68B-11.2-21.1%2.7%
CHE$6.90B24.724.4%8.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.1%
緩やかな成長
4四半期純利益CAGR
0.4%
収益性の緩やかな改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月26日
|
EPS:$0.19
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月10日|
    売上高: $522.87M+13.4%
    |
    EPS: $0.07+63.2%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月11日|
    売上高: $498.23M+8.4%
    |
    EPS: $0.19-568.0%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月12日|
    売上高: $471.40M+9.2%
    |
    EPS: $-0.51+1171.8%
    予想を下回る

  • Form 10-K/A - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年4月28日|
    売上高: $1.83B+13.2%
    |
    EPS: $0.04-20.3%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月3日|修正版データを参照

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月12日|
    売上高: $461.14M+14.7%
    |
    EPS: $0.04-83.2%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月9日|
    売上高: $459.71M+13.9%
    |
    EPS: $-0.04-129.0%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月10日|
    売上高: $431.71M+10.5%
    |
    EPS: $-0.04-84.0%
    予想を下回る